Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

But, in a large-scale cohort study, relative to warfarin, there was a nonsignificant tendency for lower rates of myocardial infarction with dabigatran among vitamin K antagonists (VKA) "new starters" users; however, there was a nonsignificant trend for increased occurrence of myocardial infarction among the prior VKA-experienced users.
Novel oral anticoagulants in non-valvular atrial fibrillation.
Cardiovasc Hematol Agents Med Chem · 2014 · PMC4428103
122 Boswellia serrata extract has been evaluated in a placebo-controlled trial, showing a nonsignificant trend in favor of active treatment. 123 Thiopurines, methotrexate, and anti-TNF therapy In patients not responding to budesonide or other treatment alternatives, immunosuppressive therapy may be carefully considered, although the evidence is virtually absent. 2 , 3 , 28 In an open study, azathioprine ind
However, the benefits from Mongolian oak were also likely offset in part by the impacts of MAP and MAT, as discussed above, resulting in a nonsignificant trend in foliar N concentration for Dahurian larch across the ecotone. 4.3 Interspecific differences of foliar 15 N abundance and Δδ 15 N across the temperate-boreal forest ecotone Mongolian oak and Dahurian larch had distinct patterns of foliar δ 15 N and Δδ 15 N across the ecotone ( Figs. 3 d, f), consistent with our second hypothesis.
We observed a nonsignificant trend toward increased HSC frequency only in cases where hematopoietic cells expressed TLR2 (WT→WT and WT→ Tlr2 −/− ; Figure 4a ); however, spleen HSPCs increased in all three chimeric groups ( Figures 4b and c ), suggesting that TLR2 expression on either radioresistant (that is, mostly stromal) or radiosensitive (hematopoietic) cells is sufficient to induce some mobilization (or expansion) of spleen HSPCs.
Similarly, there was a nonsignificant trend toward a reduction in the percentage of patients with AIS who were treated with alteplase outside of the target DTN window of less than 60 minutes from ER arrival (67.3% of patients receiving alteplase greater than 60 minutes after ED presentation with symptoms of AIS at baseline vs. 22.2% of patients at 6 months; Figure 3B ).